Swissmedic Approval: BeiGene’s BRUKINSA to Treat WM

Swissmedic Approval: BeiGene’s BRUKINSA to Treat WM

BeiGene has announced their Bruton’s tyrosine kinase (BTK) inhibitor BRUKINSA (zanubrutinib) has been approved by Swissmedic to treat adult patients with Waldenström’s macroglobulinemia (WM). WM is a rare B-cell lymphoma that is primarily found in bone marrow and...